(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 4.5MM | +23% |
Gross Profit | 3.5MM | - |
Cost Of Revenue | 993K | +74% |
Operating Income | -26.4MM | +78% |
Operating Expenses | 30MM | - |
Net Income | -27.4MM | +74% |
R&D | 12.8MM | +72% |
G&A | 17.1MM | +62% |
Amortization | 300K | - |
Interest Expense | 2MM | +11% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Rajeev Saggar, Chief Medical Officer of Liquidia Corp (NASDAQ:LQDA), has sold 7,530 shares of the company on March 18, 2024, according to a recent SEC filing.
Michael Kaseta, the Chief Financial Officer and Chief Operating Officer of Liquidia Corp (NASDAQ:LQDA), has sold 12,166 shares of the company on March 18, 2024, according to a recent SEC filing.
Liquidia Corporation (NASDAQ:LQDA) Q4 2023 Earnings Call Transcript March 13, 2024 Liquidia Corporation misses on earnings expectations. Reported EPS is $-0.42 EPS, expectations were $-0.23. LQDA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome everyone to […]
Liquidia ( NASDAQ:LQDA ) Full Year 2023 Results Key Financial Results Revenue: US$17.5m (up 9.7% from FY 2022). Net...
Q4 2023 Liquidia Corp Earnings Call
Key Financial Highlights and Corporate Updates
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -82.61% and 14.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Preparing to launch YUTREPIA™ (treprostinil) inhalation powder upon final FDA approvalFederal Circuit rejected request by United Therapeutics for rehearing of earlier decision finding ‘793 Patent invalidAdvancing industry leading portfolio for inhaled treprostinil with YUTREPIA and sustained-release program L606Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) (Liquidia or the Company) today reported financial
Pliant Therapeutics, Inc. (PLRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MORRISVILLE, N.C., March 06, 2024 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2023 financial results on Wednesday, March 13, 2024. The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of on